Plain-English translation of NCT07297667 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which is a type of immune cell therapy designed to help your body recognize and fight cancer cells. works by training your immune cells to identify a specific protein called GPNMB that appears on certain cancers. The study will test different doses of this medication in patients with three types of advanced cancer: alveolar soft part sarcoma, triple negative breast cancer, and renal cell carcinoma.
Current treatments for these advanced cancers don't work well for everyone, and many patients run out of effective options. This trial is exploring whether this new medication can help by giving the immune system a better way to attack cancer cells.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will first undergo a procedure called leukapheresis, where your immune cells are collected from your blood. Your cells will then be sent to a lab to be modified with the new therapy. Once ready, you will receive an infusion of the modified cells back into your body. You will need to commit to regular visits at the trial center for at least 12 months to allow doctors to monitor how the treatment works and watch for any side effects.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
Canada